



# PROGRAM

September 29 – October 1, 2021  
Eurasian Congress of Internal Medicine

GTM +3

## September 29, 2021

## DAY 1 OF THE CONGRESS

**09:40-10:00 AM** Room №1. Opening of the Conference

**Welcome speech:** A.G. Arutyunov (Russia, Moscow)  
I.G. Nikitin (Russia, Moscow)

**10:00-12:20 AM** Room №1. Plenary session “Comorbidities at the turn of 2021 and 2022”

- **DOAC safety issues in elderly patients with AF**  
G.P. Arutyunov (Moscow, Russia)
- **20 months with COVID-19. Eurasian Register “ACTIV”**  
A.G. Arutyunov (Moscow, Russia)
- **Wrapping up 2021. New trends in CHF**  
Petar Seferovic (Belgrade, Serbia)
- **Asymptomatic hyperuricemia and comorbidity issues**  
V.I. Mazurov (Saint Petersburg, Russia)
- **CKD. Unified therapeutic diagnosis**  
M.M. Batyushin (Rostov-on-Don, Russia)
- **PATE and in situ thrombus, more frequent than expected**  
Marco Cattaneo (Milan, Italy)
- **COPD: changes of 2021, expectations of 2022**  
Z.P. Aisanov (Moscow, Russia)
- **Influenza vaccine prophylaxis as a tool for cardiovascular risk management**  
I.G. Nikitin (Moscow, Russia)
- **Evolution of prevention and etiotropic therapy of COVID-19**  
D.S. Fomina (Moscow, Russia)

**12:20-12:45 PM** The session is held only on the Russian version of the site (in Russian). Room №1. Panel discussion “Pro vs Contra”

- **A cardiologist's and GP's perspective on controlling AH. Panel discussion “Pro vs Contra”**  
Mozheyko M.E. (Russia, Yaroslavl), O.P. Rotar (Russia, Saint Petersburg)

**12:45-13:30 PM** Break

Room №1	Room №2	Room №3	Room №4	Room №5	Room №6
<p>The session is held only on the Russian version of the site (in Russian)</p> <p><b>Special MEDIS session</b></p> <p>“Prediabetes in medical practice: pitfalls and white spots of carbohydrate metabolism disorder”</p> <p>(sponsored by Merck, not accredited for CME credits)</p> <p>Chairpersons: A.G. Arutyunov (Russia, Moscow), E.N. Grineva (Russia, Saint Petersburg)</p> <ul style="list-style-type: none"> <li>• What can the diagnosis of prediabetes mean? E.N. Grineva (Russia, Saint Petersburg)</li> <li>• Complications of prediabetes: do not miss the right moment Yu.Sh. Khalimov (Russia, Saint Petersburg)</li> <li>• Carbohydrate metabolism disorders in the COVID-19 era: What we can do for our patients A.Yu. Babenko (Russia, Saint Petersburg)</li> </ul>	<p>The session is held only on the Russian version of the site (in Russian)</p> <p>Symposium</p> <p>“Arterial hypertension therapy in the COVID-19 era: practicalities and expectations”</p> <p>(sponsored by Sanofi, not accredited for CME credits)</p> <p>Chairperson: G.P. Arutyunov (Russia, Moscow)</p> <ul style="list-style-type: none"> <li>• Current AH therapy in compliance with clinical guidelines of leading cardiology societies G.P. Arutyunov (Russia, Moscow)</li> <li>• Role of diuretics in clinical guidelines and in practice: myths and facts S.R. Gilyarevsky (Russia, Moscow)</li> <li>• Fixed combinations with a calcium antagonist: what should guide your choice? S.V. Nedogoda (Russia, Volgograd)</li> </ul>	<p>Symposium</p> <p>“Sleep disorders in the GP’s practice”</p> <p>Chairperson: A.L. Kalinkin (Russia, Moscow)</p> <ul style="list-style-type: none"> <li>• Function of sleep A.L. Kalinkin (Russia, Moscow), I.N. Pigarev (Russia, Moscow)</li> <li>• Sleep and brain health Claudio Bassetti (Zürich, Switzerland)</li> <li>• Resistant arterial hypertension and OSAS Yu.V. Sviryayev (Russia, Saint Petersburg)</li> <li>• Sleep disorders – unaccounted risk factors in GP’s practice A.L. Kalinkin (Russia, Moscow)</li> </ul>	<p>The session is held only on the Russian version of the site (in Russian)</p> <p>Symposium</p> <p>“New reality: patients with arterial hypertension and visceral obesity in the post-COVID period”</p> <p>(sponsored by Stada, not accredited for CME credits)</p> <p>Chairperson: Zh.D. Kobalava (Russia, Moscow)</p> <ul style="list-style-type: none"> <li>• Arterial hypertension: 2021 hot discussion topics Zh.D. Kobalava (Russia, Moscow)</li> <li>• Nuances of 24-hour blood pressure monitoring in the post-COVID period A.G. Arutyunov (Russia, Moscow)</li> <li>• Relevance and complexity of 24-hour BP control in patients with AH and visceral obesity Y.A. Karpov (Russia, Moscow)</li> </ul>	<p>The session is held only on the Russian version of the site (in Russian)</p> <p>Symposium</p> <p>“What do experts discuss? Cardiologists debate on comorbid patients with cardiovascular disease”</p> <p>(sponsored by TEVA, not accredited for CME credits)</p> <p>Chairperson: Yu.A. Karpov (Russia, Moscow)</p> <ul style="list-style-type: none"> <li>• Comorbid patients with cardiovascular disease: who are they? S.V. Nedogoda (Russia, Volgograd)</li> </ul> <p>Panel discussion – 15 minutes</p> <ul style="list-style-type: none"> <li>• CVD therapy in the new reality. Is there a need for change? S.K. Zyryanov (Russia, Moscow)</li> </ul> <p>Panel discussion – 15 minutes</p>	<p>Symposium</p> <p>“An update in metabolic and reproductive endocrinology”</p> <p>Chairpersons: Djuro Macut (Serbia, Belgrade), Goran Cvijovic (Serbia, Belgrade)</p> <ul style="list-style-type: none"> <li>• Gestational diabetes mellitus: an endocrine approach Djuro Macut (Serbia, Belgrade)</li> <li>• Metabolic and reproductive effects of melatonin therapy Goran Cvijovic (Serbia, Belgrade)</li> <li>• Is every woman with polycystic ovary syndrome at risk to develop type 2 diabetes? Sarantis Livadas (Greece, Athens)</li> <li>• Metabolic surgery: is it just about insulin resistance control? Jose Silva Nunes (Portugal, Lisbon)</li> </ul>

Room №1	Room №2	Room №3	Room №4	Room №5	Room №6
<p>There is no broadcast</p>	<p>The session is held only on the Russian version of the site (in Russian)</p> <p>Symposium            “Diabetes mellitus and IHD are two epidemics of our time. What therapy is needed when they are combined”  <small>(sponsored by Bayer, not accredited for CME credits)</small></p> <p>Chairperson:            G.P. Arutyunov (Russia, Moscow)</p> <ul style="list-style-type: none"> <li>How to improve prognosis in a patient with IHD and diabetes mellitus                G.P. Arutyunov (Russia, Moscow)</li> <li>Is antiaggregant therapy sufficient to treat patients with high risk of cardiovascular events?                A.G. Obrezan (Russia, Saint Petersburg)</li> <li>Evidence base for anticoagulants in treatment of patients with a combination of IHD and DM                N.B. Perepech (Russia, Saint Petersburg)</li> <li>Can treatment outcomes be improved in patients with IHD and diabetic nephropathy?                N.A. Koziolova (Russia, Perm)</li> <li>Multifocal atherosclerosis in diabetic patients. What to look out for?                E.M. Nifontov (Russia, Saint Petersburg)</li> <li>A patient with IHD and diabetes mellitus. Consequences of suboptimal control                G.R. Galstyan (Russia, Moscow)</li> </ul>	<p>Symposium            “Thrombosis in the practice of general practitioners and cardiologists”</p> <p>Chairperson:            A.S. Galyavich (Russia, Kazan)</p> <ul style="list-style-type: none"> <li>Thrombosis: from etiopathogenesis to treatment                A.S. Galyavich (Russia, Kazan)</li> <li>Intracardiac thrombosis. Clinical review                Z.M. Galeyeva (Russia, Kazan)</li> <li>Antithrombotic treatment in diabetes mellitus                L.V. Baleyeva (Russia, Kazan)</li> <li>Antithrombotic treatment after COVID-19                G.M. Kamalov (Russia, Kazan)</li> <li>Closing remarks                A.S. Galyavich (Russia, Kazan)</li> </ul>	<p>Symposium            “Current issues in digestive pathology”</p> <p>Chairperson:            I.G. Bakulin (Russia, Saint Petersburg)</p> <ul style="list-style-type: none"> <li>A new paradigm for the pathogenesis of digestive diseases                I.V. Maev (Russia, Moscow)</li> <li>Inflammatory bowel disease: current issues                I.G. Bakulin (Russia, Saint Petersburg)</li> <li>Antibiotic-associated diarrhea: current approaches to diagnostics and treatment                N.V. Bakulina (Russia, Saint Petersburg)</li> <li>Gut microbiota: do we know everything about the pathogenesis of digestive diseases?                E.B. Avalueva (Russia, Saint Petersburg)</li> <li>Liver pathology in a new coronavirus infection: a gastroenterologist's view                E.V. Skazyvaeva (Russia, Saint Petersburg)</li> </ul>	<p>Symposium            “Results of new prospective clinical trials”</p> <p>Chairperson:            O.S. Fedorova (Russia, Moscow)</p> <ul style="list-style-type: none"> <li>Use of olokizumab in patients with a new coronavirus infection                S.V. Topolyanskaya (Russia, Moscow)</li> <li>Reducing the risk of neurocognitive impairment in cardiac patients who underwent cardiopulmonary bypass surgery                I.Yu. Chigareva (Russia, Moscow)</li> <li>Effect of combined glucose-normalising therapy on the structural and functional status of the heart in type 2 diabetic patients                V.R. Miminoshvili (Ukraine, Donetsk)</li> <li>Prognostic value of the CLIF-C scale for a group of hospitalized patients with cirrhosis                D.I. Gavrilenko (Belarus, Minsk)</li> <li>Features of the clinical course of post-COVID syndrome in comorbid patients with rheumatoid arthritis in clinical practice                L.E. Sarantseva (Russia, Saint Petersburg)</li> <li>Efficacy of pharmacotherapy in patients with non-alcoholic fatty liver disease combined with arterial hypertension and type 2 diabetes mellitus                I.A. Lukonin (Russia, Krasnodar)</li> </ul>	<p>Symposium            “Cardiovascular risk management in clinical practice”</p> <p>Chairperson:            A.B. Sugraliev (Kazakhstan, Almaty),            Sh.B. Zhangelova (Kazakhstan, Almaty)</p> <ul style="list-style-type: none"> <li>Type 2 diabetes mellitus. Cardiovascular risk management                B.K. Zholdin (Kazakhstan, Aktobe)</li> <li>Assessment and management of risk factors in patients with CIHD                Sh.B. Zhangelova (Kazakhstan, Almaty)</li> <li>Assessment and management of risk factors in patients with AH                V.A. Zhakipbekova (Kazakhstan, Karaganda)</li> <li>Risk factors and issues of primary and secondary prevention of venous thrombosis in general practice                A.B. Sugraliev (Kazakhstan, Almaty)</li> </ul>

Room №1

The session is held only on the Russian version of the site  
(in Russian)

Special MEDIS session

“Cardiovascular mortality growth in the post-COVID period: from background causes to countermeasures”

(sponsored by Merck, not accredited for CME credits)

Chairperson:

G.P. Arutyunov (Russia, Moscow)

- **COVID-19 and frequent cardiovascular pathologies: a hidden threat or exaggerated significance?**  
G.P. Arutyunov (Russia, Moscow)
- **Therapeutic algorithm for post-COVID patients with frequent CV pathology. EAIM expert board data**  
A.G. Arutyunov (Russia, Moscow)
- **Is correction of drug therapy for CVDs necessary after a COVID-19 infection?**  
A.O. Konradi (Russia, Saint Petersburg)

Room №1	Room №2	Room №3	Room №4	Room №5	Room №6
<p>The session is held only on the Russian version of the site (in Russian)</p> <p>Symposium “Dyslipidemia – a turning point in history” <small>(sponsored by Abbot Laboratories 000, not accredited for CME credits)</small></p> <p>Chairperson: G.P. Arutyunov (Moscow)</p> <ul style="list-style-type: none"> <li>• The key to unlock the era of combination therapy G.P. Arutyunov (Russia, Moscow)</li> <li>• Combination therapy in lipidology: residual risk correction A.S. Alieva (Russia, St. Petersburg)</li> <li>• The role of fixed combination in the therapy of patients with dyslipidemia A.G. Obrezan (Russia, St. Petersburg)</li> <li>• Omega-3 PUFAs in the secondary prevention of myocardial infarction in patients with chronic heart failure. It is useless to say: “We do everything we can” N.A. Koziolova (Russia, Perm)</li> <li>• Panel discussion G.P. Arutyunov (Russia, Moscow)</li> </ul>	<p>The session is held only on the Russian version of the site (in Russian)</p> <p>Symposium “Vestibular vertigo. Practical approaches” <small>(sponsored by Berlin-Chemie, not accredited for CME credits)</small></p> <p>Chairperson: V.A. Parfenov (Russia, Moscow)</p> <ul style="list-style-type: none"> <li>• Unmanageable vertigo in internist practice N.A. Koziolova (Russia, Perm)</li> <li>• Vestibular vertigo: diagnosis and treatment, common diagnostic errors. Vestibular neuronitis V.A. Parfenov (Russia, Moscow)</li> <li>• Meniere’s disease. Differential diagnosis and treatment approaches A.L. Guseva (Russia, Moscow)</li> </ul>	<p>Symposium “The COVID-19 pandemic: continuing to learn lessons”</p> <p>Chairperson: E.I. Tarlovskaya (Russia, Nizhny Novgorod)</p> <ul style="list-style-type: none"> <li>• Choosing an effective target therapy window with Olokizumab A.G. Arutyunov (Russia, MOSCOW) <small>(sponsored by R-Pharm, not accredited for CME credits)</small></li> <li>• Effect of clusters of comorbidities on the severity of the course of new coronavirus infection: International Registry Analysis of Comorbid Disease Dynamics in Patients after SARSCoV-2 Infection (ACTIV) E. I. Tarlovskaya (Russia, Nizhny Novgorod)</li> <li>• Recommendations for the follow-up of CHF patients after COVID-19 A.I. Chesnikova (Russia, Rostov-on-Don)</li> <li>• Experience of rehabilitation of patients after COVID-19 M.V. Boldina (Russia, Nizhny Novgorod)</li> </ul>	<p>Symposium “Modern antibiotic therapy: about COVID-19 and beyond”</p> <p>Chairperson: S.K. Zyryanov (Russia, Moscow)</p> <ul style="list-style-type: none"> <li>• Contribution of the pandemic to antibiotic resistance. Emphasis on a broad spectrum A.O. Bykov (Russia, Moscow)</li> <li>• Pregnancy and medication. Dosing for two? E.A. Ushkalova (Russia, Moscow)</li> <li>• A patient with altered renal and hepatic function. What is important to consider? O.I. Butranova (Russia, Moscow)</li> <li>• An elderly patient: nuances of antibiotic therapy S.K. Zyryanov (Russia, Moscow)</li> </ul>	<p>Symposium of the Republic of Belarus “Difficult clinical cases”</p> <p>Chairperson: N.P. Mitkovskaya (Belarus, Minsk)</p> <ul style="list-style-type: none"> <li>• The craftiness of infective endocarditis N.P. Mitkovskaya (Belarus, Minsk)</li> <li>• Deep vein thrombosis in a comorbid patient G.P. Arutyunov (Russia, Moscow)</li> <li>• Caseous calcification of the mitral valve E.A. Grigorenko (Belarus, Minsk)</li> <li>• Clinical case of simultaneous endovascular embolization of a coronary pulmonary fistula and stenting of an extended stenosis of the anterior interventricular artery in a patient with stable angina O.L. Polonetskiy (Belarus, Minsk)</li> <li>• Patient with chronic heart failure, left bundle branch block, severe mitral regurgitation: where to start? D.B. Goncharik (Belarus, Minsk)</li> </ul>	<p>Symposium «Unified cardiovascular and metabolic approach to treatment of patients with obesity and diabetes mellitus»</p> <p>Chairpersons: G.A. Manushakyan (Moscow, Russia), A.G. Arutyunov (Moscow, Russia)</p> <ul style="list-style-type: none"> <li>• New vision of patients with metabolic disorders: when medication should be initiated? A.G. Arutyunov (Moscow, Russia)</li> <li>• Outside of glycaemia control: perspectives of therapy with GLP-1 agonists in patients with diabetes mellitus type 2 E.A. Shestakova (Moscow, Russia)</li> <li>• Drug therapy of obesity: earlier initiation makes better progress N.A. Matsiyevsky (St. Petersburg, Russia)</li> <li>• From theory to practice: personalized choice of GLP-1 agonists in wide range of clinical cases G.A. Manushakyan (Moscow, Russia)</li> </ul>

[sponsored by Bayer, not accredited for CME credits]

- **Why is a comprehensive approach important for the elderly patient with AF?**  
S.V. Villevalde (Russia, Saint Petersburg)
- **Protecting elderly patients with AF from stroke. What is always important to remember?**  
G.P. Arutyunov (Russia, Moscow)
- **Therapy safety is a significant component of comprehensive protection for the AF patient**  
A.G. Arutyunov (Russia, Moscow)
- **Nephrologist's opinion on the use of anticoagulants in patients with AF and renal dysfunction**  
M.M. Batyushin (Russia, Rostov-on-Don)
- **Protecting kidney function – can the risk of worsening kidney function in patients with AF be reduced?**  
N.A. Koziolova (Russia, Perm)
- **What do coronary risks mean for a patient with AF: what to expect and how to avoid severe consequences?**  
A.N. Yakovlev (Russia, Saint Petersburg)
- **Compliance with therapy is the key to the therapy reliability**  
S.S. Kucherenko (Russia, Saint Petersburg)
- **Annoying bleedings on DOAC therapy in patients with AF: what is to be done?**  
E.I. Tarlovskaya (Russia, Nizhny Novgorod)
- **GI bleeding and DOAC therapy. Are they interconnected?**  
N.V. Bakulina (Russia, Saint Petersburg)

12:35-13:20 PM **The session is held only on the Russian version of the site (in Russian). Room №1. Panel discussion of relevant topics**

S.V. Villevalde (Russia, Saint Petersburg), G.P. Arutyunov (Russia, Moscow), A.G. Arutyunov (Russia, Moscow), M.M. Batyushin (Russia, Rostov-on-Don), N.A. Koziolova (Russia, Perm), A.N. Yakovlev (Russia, Saint Petersburg), S.S. Kucherenko (Russia, Saint Petersburg), E.I. Tarlovskaya (Russia, Nizhny Novgorod), N.V. Bakulina (Russia, Saint Petersburg)

13:20-13:45 PM **The session is held only on the Russian version of the site (in Russian). Dedicated Zoom rooms. Q&A SESSION**

S.V. Villevalde (Russia, Saint Petersburg), G.P. Arutyunov (Russia, Moscow), A.G. Arutyunov (Russia, Moscow), M.M. Batyushin (Russia, Rostov-on-Don), N.A. Koziolova (Russia, Perm), A.N. Yakovlev (Russia, Saint Petersburg), S.S. Kucherenko (Russia, Saint Petersburg), E.I. Tarlovskaya (Russia, Nizhny Novgorod), N.V. Bakulina (Russia, Saint Petersburg)

13:45-14:30 PM **Break**

Room №1	Room №2	Room №3	Room №4	Room №5
<p><b>The session is held only on the Russian version of the site (in Russian)</b></p> <p><b>Symposium</b>  <b>“A new world and new rules for the management of patients with AH”</b>  <small>(sponsored by TEVA, not accredited for CME credits)</small></p> <p><b>Chairperson:</b>  <b>G.P. Arutyunov (Russia, Moscow)</b></p> <ul style="list-style-type: none"> <li>• <b>Time for change. Challenges in the therapy of AH patients</b>  N.A. Koziolova (Russia, Perm)</li> <li>• <b>AH in 2021. Let's dot the i's and cross the t's after the ESC Congress</b>  E.V. Privalova (Russia, Moscow)</li> </ul>	<p><b>Symposium</b>  <b>“Post-COVID: expected complications”</b></p> <p><b>Chairperson:</b>  <b>A.G. Arutyunov (Russia, Moscow)</b></p> <ul style="list-style-type: none"> <li>• <b>How long do antibodies persist after COVID-19?</b>  V.V. Shustov (Russia, Moscow)</li> <li>• <b>Long-term COVID-19 consequences</b>  A.G. Arutyunov (Russia, Moscow)</li> <li>• <b>CHF in the post-COVID period</b>  Bojan Vrtovec (Slovenia, Ljubljana)</li> <li>• <b>Post-COVID as a new risk category</b>  Goran Krstačić (Croatia, Zagreb)</li> <li>• <b>CKD in the post-COVID period</b>  M.M. Batyushin (Russia, Rostov-on-Don)</li> </ul>	<p><b>Symposium</b>  <b>“Complex and unresolved issues in the management of patients with respiratory pathology and cardiovascular diseases”</b></p> <p><b>Chairperson:</b>  <b>E.I. Tarlovskaya (Russia, Nizhny Novgorod)</b></p> <ul style="list-style-type: none"> <li>• <b>Cardiovascular disease in patients with COPD: breaking stereotypes, following guidelines</b>  A.I. Chesnikova (Russia, Rostov-on-Don)</li> <li>• <b>Tactics for antianginal therapy in patients with IHD concomitant with bronchial asthma</b>  N.Yu. Grigoryeva (Russia, Nizhny Novgorod)</li> <li>• <b>Nuances of the management of patients with bronchial asthma and cardiovascular diseases</b>  M.V. Boldina (Russia, Nizhny Novgorod)</li> <li>• <b>Effect of drugs used to treat cardiac diseases on the severity of the course of respiratory viral infections</b>  E.I. Tarlovskaya (Russia, Nizhny Novgorod)</li> </ul>	<p><b>Symposium</b>  <b>“Osteoporosis in clinical practice. Clinical review”</b></p> <p><b>Chairperson:</b>  <b>O.M. Lesniak (Russia, Saint Petersburg)</b></p> <ul style="list-style-type: none"> <li>• <b>Welcome speech</b>  O.M. Lesniak (Russia, Saint Petersburg)</li> <li>• <b>Compression fractures of vertebral bodies in GP's practice</b>  L.P. Evstigneeva (Russia, Ekaterinburg)</li> <li>• <b>Vitamin D deficiency in osteoporosis and beyond</b>  T.L. Karonova (Russia, Saint Petersburg)</li> <li>• <b>Differential diagnosis of osteoporosis with other metabolic skeletal diseases</b>  O.M. Lesniak (Russia, Saint Petersburg)</li> <li>• <b>How to prevent repeated fractures due to osteoporosis</b>  O.B. Ershova (Russia, Yaroslavl)</li> </ul>	<p><b>Symposium of Armenian Association of Internal Medicine</b></p> <p><b>Chairperson:</b>  <b>L.A. Manukyan (Armenia, Yerevan)</b></p> <ul style="list-style-type: none"> <li>• <b>Caring for the elderly with dementia. UK experience</b>  Seda Boghossian-Tighe (England, Walton-on-Thames)</li> <li>• <b>Bronchial asthma: problems and solutions</b>  M.R. Oganyan (Armenia, Yerevan)</li> <li>• <b>Correction of endothelial dysfunction and metabolic disorders in the post-COVID period</b>  L.A. Manukyan (Armenia, Yerevan)</li> </ul>

- **Diabetes is a global pandemic. Trends and expectations for the next 5 years**  
V.V. Salukhov (Russia, Saint Petersburg)
- **Artificial intelligence in assessing the severity of a new coronavirus infection course**  
N.Yu. Grigoryeva (Russia, Nizhny Novgorod)
- **What to expect in the treatment of CHF over the next 5 years**  
I.I. Shaposhnik (Russia, Chelyabinsk)

Room №1	Room №2	Room №3	Room №4	Room №5
<p><b>The session is held only on the Russian version of the site (in Russian)</b></p> <p><b>Symposium</b>  <b>Treating Heart Failure: Time to Seize New Opportunities</b>  <small>(sponsored by Boehringer Ingelheim, not accredited for CME credits)</small></p> <p><b>Chairperson:</b>  <b>Yu.M. Lopatin. (Russia, Volgograd)</b></p> <ul style="list-style-type: none"> <li>• <b>New algorithm for treatment of heart failure with reduced ejection fraction – how cardiologist can incorporate modern approaches into clinical practice?</b>                      S.V. Nedogoda (Russia, Volgograd)</li> <li>• <b>Empagliflozin in patients with HF across the ejection fraction spectrum – pooled data of the EMPEROR trial</b>                      G.P. Arutyunov (Russia, Moscow)</li> <li>• <b>Diabetes mellitus type 2 and heart failure: there is still something to strive for an endocrinologist and a cardiologist</b>                      V.V. Salukhov (Russia, Saint Petersburg)</li> </ul>	<p><b>The session is held only on the Russian version of the site (in Russian)</b></p> <p><b>Symposium</b>  <b>Innovative Approach to Cardiovascular Risk Stratification in Outpatient Practice</b>  <small>(sponsored by Abbott Laboratories LLC, not accredited for CME credits)</small></p> <p><b>Chairperson:</b>  <b>A.G. Arutyunov (Russia, Moscow)</b></p> <ul style="list-style-type: none"> <li>• <b>Biomarkers as predictors of cardiovascular risk</b>                      G.P. Arutyunov (Russia, Moscow)</li> <li>• <b>New potential of high-sensitivity troponin-I according to domestic research</b>                      A.V. Kontsevaya (Russia, Moscow)</li> <li>• <b>The role of high-sensitivity troponin-I in the management of cardiovascular risk in patients. Croatia's experience</b>                      Goran Krstacic (Croatia, Zagreb)</li> <li>• <b>High-sensitivity troponin-I in patients with chronic cardiovascular diseases</b>                      N.A. Koziolova (Russia, Perm)</li> <li>• <b>Panel discussion</b>                      A.G. Arutyunov (Russia, Moscow)</li> </ul>	<p><b>Symposium</b>  <b>From AH to CHF – changing treatment regimens</b></p> <p><b>Chairperson:</b>  <b>I.S. Yavelov (Russia, Moscow)</b></p> <ul style="list-style-type: none"> <li>• <b>PATE in patients with CHF before and after COVID-19</b>                      I.S. Yavelov (Russia, Moscow)</li> <li>• <b>Disease-modifying therapy as a main new principle of CHF treatment</b>                      I.V. Zhironov (Russia, Moscow)</li> <li>• <b>AH therapy: how to prevent CHF development. New opportunities</b>                      T.N. Novikova (Russia, Saint Petersburg)</li> </ul>	<p><b>Symposium</b>  <b>Current Issues in Nephrology – Facing the General Practitioner</b></p> <p><b>Chairperson:</b>  <b>M.M. Batyushin (Russia, Rostov-on-Don)</b></p> <ul style="list-style-type: none"> <li>• <b>Dietary salt intake and CKD, is arterial hypertension the only link?</b>                      Tatsuo Shimosawa (Japan, Tokyo)</li> <li>• <b>Acute kidney injury in CHF</b>                      M.M. Batyushin (Russia, Rostov-on-Don)</li> <li>• <b>Risk factors of diabetic nephropathy progression: it is not about hyperglycemia</b>                      Janaka Karalliedde (England, London)</li> </ul>	<p><b>Symposium</b>  <b>New insights in Cardiovascular Medicine</b></p> <p><b>Chairperson:</b>  <b>Plinio Cirillo (Naples, Italy)</b></p> <ul style="list-style-type: none"> <li>• <b>Molecular therapies and models for cardiovascular disease</b>                      Francesco Loffredo (Trieste, Italy)</li> <li>• <b>The emerging role of non conventional risk factors in cardiovascular disease</b>                      Plinio Cirillo (Naples, Italy)</li> <li>• <b>Colchicine and cardiovascular disease: the second youth of an "old" drug</b>                      Giovanni Cimmino (Naples, Italy)</li> <li>• <b>Non angiographically significant coronary stenosis: to treat or not to treat? The role of Fractional Flow Reserve to guide coronary revascularization</b>                      Luigi Di Serafino (Naples, Italy)</li> </ul>



11:45 AM-13:45 PM Room №1. Speed session

11:45 AM-12:35 PM **The session is held only on the Russian version of the site (in Russian).**  
Speed session "Treating heart failure: it is not as simple as it seems" (sponsored by Boehringer Ingelheim, not accredited for CME credits)

- **Main results of the EMPEROR-Preserved trial**  
Stefan D. Anker  
(Germany, Berlin)
- **Main mechanisms of SGLT2 inhibitors impact on heart failure outcomes**  
Yu.Sh. Khalimov  
(Russia, Saint Petersburg)
- **Nephroprotective effects of SGLT2 inhibitors in heart failure**  
Janaka Karalliedde  
(England, London)
- **Safety of SGLT2 inhibitors in patients without type 2 diabetes**  
I.V. Zhirov  
(Russia, Moscow)
- **A universal definition and a new classification of heart failure**  
S.V. Nedogoda  
(Russia, Volgograd)
- **Optimising therapy for heart failure depending on a patient profile**  
G.P. Arutyunov  
(Russia, Moscow)
- **New European algorithms for the treatment of heart failure**  
Yu.M. Lopatin  
(Russia, Volgograd)

12:35-13:45 PM **The session is held only on the Russian version of the site (in Russian).** Room №1. Panel discussion of relevant topics

Stefan D. Anker (Germany, Berlin), Yu.Sh. Khalimov (Russia, Saint Petersburg), Janaka Karalliedde (England, London), I.V. Zhirov (Russia, Moscow), S.V. Nedogoda (Russia, Volgograd), G.P. Arutyunov (Russia, Moscow), Yu.M. Lopatin (Russia, Volgograd)

13:45-14:30 PM Break

Room №1	Room №2	Room №3	Room №4	Room №5
<p>The session is held only on the Russian version of the site (in Russian)</p> <p><b>Symposium</b>  <b>“Features of a vulnerable patient population with heart failure with normal ejection fraction (HFNEF) after a decompensation episode: opportunities to correct the disease trajectory”</b>  <small>(sponsored by Bayer, not accredited for CME credits)</small></p> <p><b>Chairperson:</b>  <b>Yu.M. Lopatin (Russia, Volgograd)</b></p> <ul style="list-style-type: none"> <li>• <b>A decompensation episode of HFNEF is a turning point in the clinical course of the disease</b> A.G. Arutyunov (Russia, Moscow)</li> <li>• <b>Clinical practice challenges in reducing the residual risk of recurrent events</b> S.R. Gilyarevsky (Russia, Moscow)</li> <li>• <b>Pathophysiological significance of soluble guanylate cyclase (sGC) as a potential therapeutic target in HFNEF</b> Zh.D. Kobalova (Russia, Moscow)</li> <li>• <b>Prospects for improved prognosis after an episode of decompensated HF in the light of the VICTORIA trial results</b> Yu.M. Lopatin (Russia, Volgograd)</li> <li>• <b>Discussion / Closing remarks</b></li> </ul>	<p>The session is held only on the Russian version of the site (in Russian)</p> <p><b>Symposium</b>  <b>“Cardiovascular therapy: scientific advances and clinical practice”</b>  <small>(sponsored by Berlin-Chemie, not accredited for CME credits)</small></p> <p><b>Chairperson:</b>  <b>V.S. Gurevich (Russia, Saint Petersburg)</b></p> <ul style="list-style-type: none"> <li>• <b>The role of organ protection in the treatment of an AH patient</b> V.S. Gurevich (Russia, Saint Petersburg)</li> <li>• <b>Stable angina: from clinical guidelines to clinical practice</b> E.I. Baranova (Russia, Saint Petersburg)</li> <li>• <b>Beta-blockers in the treatment of elderly patients: an assessment of current attitudes and therapeutic options</b> A.P. Rebrov (Russia, Saratov)</li> </ul>	<p><b>Symposium</b>  <b>“Thyroid diseases”</b></p> <p><b>Chairpersons:</b>  <b>O.S. Fedorova (Russia, Moscow),  A.R. Volkova (Russia, Saint Petersburg)</b></p> <ul style="list-style-type: none"> <li>• <b>Subclinical hypothyroidism: to treat or not to treat</b> E.M. Patrakeyeva (Russia, Saint Petersburg)</li> <li>• <b>The vicious circle of thyroid metabolism in patients with CKD</b> A.R. Volkova (Russia, Saint Petersburg)</li> <li>• <b>Nodular goiter in questions and answers. Current approaches to diagnostics and treatment</b> O.S. Fedorova (Russia, Moscow)</li> <li>• <b>Monitoring of patients with operated thyroid gland</b> O.A. Nechaeva (Russia, Moscow)</li> </ul>	<p>The session is held only on the Russian version of the site (in Russian)</p> <p><b>Symposium</b>  <b>“New opportunities to influence remodeling processes at different stages of the cardiovascular continuum”</b>  <small>(sponsored by Novartis, not accredited for CME credits)</small></p> <p><b>Chairpersons:</b>  <b>G.P. Arutyunov (Russia, Moscow),  V.V. Tyrenko (Russia, Saint Petersburg)</b></p> <ul style="list-style-type: none"> <li>• <b>The natriuretic peptide system: physiological role. Involvement in the pathogenesis of AH and CHF. Application points in pharmacotherapy</b> V.N. Khirmanov (Russia, Saint Petersburg)</li> <li>• <b>Class of angiotensin receptor-neprilysin inhibitors (ARNIs). New AH therapy options</b> G.P. Arutyunov (Russia, Moscow)</li> <li>• <b>The ARNI class in de novo patients with CHF: the earlier, the better</b> V.V. Tyrenko (Russia, Saint Petersburg)</li> </ul>	<p><b>Symposium</b>  <b>“Results of new prospective clinical trials”</b></p> <p><b>Chairperson:</b>  <b>G.A. Manushakyan (Russia, Moscow)</b></p> <ul style="list-style-type: none"> <li>• <b>Glycaemic profile in patients with new coronavirus infection COVID-19</b> S.V. Perepelitsa (Russia, Kaliningrad)</li> <li>• <b>Features of the expanded cytokine profile in patients with COVID-19</b> E.V. Koroleva (Russia, Nizhny Novgorod)</li> <li>• <b>COPD with frequent severe exacerbations: the role of comorbid pathology</b> A.R. Zinnatullina (Russia, Kazan)</li> <li>• <b>Acute-to-chronic liver failure syndrome: applicability of a new model in clinical practice</b> D.I. Gavrilenko (Belarus, Minsk)</li> <li>• <b>COVID-19-associated structural and functional heart changes in elderly patients</b> L.A. Bodretskaya (Ukraine, Kiev)</li> <li>• <b>Clinical features in patients with myocardial infarction and diabetic nephropathy carrying the polymorphic variants of NOS3, APOE and SLC01B1</b> A.V. Siverina (Russia, Saint Petersburg)</li> <li>• <b>Dynamic assessment of heart rate variability in physically trained individuals</b> I.I. Novikov (Russia, Saint Petersburg)</li> </ul>